NCT06728189

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors

Recruiting now Phase 1 Last updated 11 December 2024

What this trial tests

Phase 1 trial testing CAR-NKT Cells treatment in Advanced Malignant Solid Tumors in 13 participants. Currently enrolling.

Timeline

14 November 2024

Primary endpoint
17 October 2026

17 October 2026

Quick facts

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	14 November 2024
Primary completion	17 October 2026
Estimated completion	17 October 2026
Sites	1 location across China

Drugs / interventions tested

• CAR-NKT Cells treatment — full drug profile →

Conditions studied

• Advanced Malignant Solid Tumors — all drugs for Advanced Malignant Solid Tumors →

Sponsor

Peking University Cancer Hospital & Institute

Who can join

Adults 18 to 75, any sex, with Advanced Malignant Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC738 in the treatment of advanced malignant solid tumors.

Condition or disease：advanced malignant solid tumors Intervention/treatment：Biological: CD70 CAR-NKT cells Phase：Phase 1

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
   Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6
2. Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.
   Singer M, Valerin J, Zhang Z, Zhang Z, et al · · 2025 · cited 6× · PMID 39936958 · DOI 10.3390/cells14030166
3. CAR-iNKT cells: redefining the frontiers of cellular immunotherapy.
   Niedzielska M, Chalmers A, Popis MC, Altman-Sharoni E, et al · · 2025 · cited 2× · PMID 40718496 · DOI 10.3389/fimmu.2025.1625426
4. Mucosal-Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets.
   Zhu C, Huai Q, Du Y, Li X, et al · · 2025 · cited 1× · PMID 41179703 · DOI 10.1002/mco2.70445
5. Facts and Hopes of Chimeric Antigen Receptor-Redirected NK T Cells.
   Courtney AN, Zhou X, Tian G, Wang Y, et al · · 2025 · cited 1× · PMID 41118265 · DOI 10.1158/1078-0432.ccr-25-0197
6. Nonclassical MHC-I Molecules: Emerging Therapeutic Targets in Next-Generation Immunotherapy.
   He W, McMichael AJ. · · 2026 · PMID 42027260 · DOI 10.1002/mco2.70742
7. Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions.
   Song Y, Mo Y, Chen S, Chen Y, et al · · 2026 · PMID 41768369 · DOI 10.1002/mco2.70635
8. Innate iNKT cells: from biological insight to clinical impact.
   Rotolo A, Mason NJ, Exley MA. · · 2025 · PMID 41000376 · DOI 10.3389/fimmu.2025.1653183